ArticleScientific reports2026
Engineered novel dually cross-linked hydrogel system embedded with Apigenin-cyclodextrin complex for surgical wound healing.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Surgical wounds present a critical clinical challenge often requiring advanced therapeutic strategies to accelerate healing and enhance tissue regeneration. Herein, we engineered novel dually cross-linked hydrogel system incorporating an Apigenin-β-cyclodextrin (API-βCD) inclusion complex for enhanced wound therapy. First, the API-βCD inclusion complex was prepared and characterized comprehensively through nuclear magnetic resonance (NMR) and Fourier transform infrared (FTIR) spectroscopy, X-ray diffractometry (XRD), scanning electron microscopy (SEM), molecular docking and phase solubility studies. Then, dually cross-linked hydrogel matrix embedded with the API-βCD complex was synthesized and assessed for comprehensive structural, mechanical and physiochemical properties. In vitro release, ex vivo permeation, cell viability, antibacterial activity, wound closure and anti-inflammatory cells analyses of the API-βCD hydrogel were performed. Results confirmed the formation of successful inclusion complex. Phase solubility study demonstrated 66.8 ~ fold increase in the aqueous solubility of API. FTIR analysis confirmed successful crosslinking within the hydrogel matrix. Moreover, API-βCD hydrogel exhibited enhanced mechanical properties, porous architecture and optimal swelling and degradation behaviors. In vitro and ex vivo studies demonstrated sustained release, minimal permeation and enhanced disposition (57%) of API in skin layers, higher cell viability, and augmented antibacterial potential. Additionally, API-βCD hydrogel demonstrated significantly accelerated wound healing with 97% wound closure and noticeable downregulation of inflammatory parameters, such as TNF-α and IL-1β. These results concluded that API-βCD hydrogel may improve the solubility, dissolution of API and holds promising potential for regenerative wound management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.